Darolutamide and Hormone Therapy Before Prostate Surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have prostate cancer that has not spread beyond the pelvis and is considered high-risk (large tumor, high Gleason score, or high PSA).
- You have not had hormone therapy, radiation, or chemotherapy for prostate cancer before.
- You are healthy enough for surgery and daily activities (ECOG score 0 or 1).
- Your kidney, liver, and blood cell counts are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
This study looks at whether combining the drug darolutamide with standard hormone therapy can help men whose prostate cancer was found in their pelvic lymph nodes after prostate removal surgery. It aims to see if this treatment helps keep the cancer from coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.